ATE284898T1 - Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind - Google Patents

Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind

Info

Publication number
ATE284898T1
ATE284898T1 AT00959292T AT00959292T ATE284898T1 AT E284898 T1 ATE284898 T1 AT E284898T1 AT 00959292 T AT00959292 T AT 00959292T AT 00959292 T AT00959292 T AT 00959292T AT E284898 T1 ATE284898 T1 AT E284898T1
Authority
AT
Austria
Prior art keywords
synthetic
expression
human cells
papillomavirus
genes optimized
Prior art date
Application number
AT00959292T
Other languages
English (en)
Inventor
Michael P Neeper
William L Mcclements
Kathrin U Jansen
Loren D Schultz
Ling Chen
Xin-Min Wang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26847958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE284898(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE284898T1 publication Critical patent/ATE284898T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT00959292T 1999-08-25 2000-08-21 Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind ATE284898T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15072899P 1999-08-25 1999-08-25
US21014300P 2000-06-07 2000-06-07
PCT/US2000/022932 WO2001014416A2 (en) 1999-08-25 2000-08-21 Synthetic papillomavirus genes optimized for expression in human cells

Publications (1)

Publication Number Publication Date
ATE284898T1 true ATE284898T1 (de) 2005-01-15

Family

ID=26847958

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959292T ATE284898T1 (de) 1999-08-25 2000-08-21 Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind

Country Status (9)

Country Link
EP (1) EP1212358B1 (de)
JP (1) JP4799789B2 (de)
AT (1) ATE284898T1 (de)
AU (1) AU772611B2 (de)
CA (1) CA2381991A1 (de)
DE (1) DE60016765T2 (de)
ES (1) ES2233437T3 (de)
PT (1) PT1212358E (de)
WO (1) WO2001014416A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
DE60124918T2 (de) * 2000-07-21 2007-08-02 Glaxo Group Ltd., Greenford Kodon-optimierte papillomavirussequenzen
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
ATE354662T1 (de) 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
EP2842964A1 (de) 2001-06-05 2015-03-04 Curevac GmbH Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20050118139A1 (en) * 2001-08-23 2005-06-02 Lingyi Huang Vaccine using papilloma virus e proteins delivered by viral vector
AU2002347317B2 (en) 2001-11-30 2008-06-26 Isis Innovation Limited Vaccine
FR2839072A1 (fr) 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
ES2381964T3 (es) * 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ATE555127T1 (de) 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
DE602005020913D1 (de) * 2004-03-24 2010-06-10 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
US8101342B2 (en) * 2006-08-28 2012-01-24 Sungkyunkwan University Foundation For Corporate Collaboration DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
US8420103B2 (en) 2007-01-30 2013-04-16 Transgene S.A. Papillomavirus vaccines
JP5474767B2 (ja) * 2007-05-15 2014-04-16 トランジェーヌ、ソシエテ、アノニム 多重遺伝子発現のためのベクター
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP2638058B1 (de) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase-peptid-konjugat-impfstoffe gegen staphylococcus aureus
MX360449B (es) * 2011-10-12 2018-11-01 Univ Pennsylvania Vacunas para el virus del papiloma humano y metodos para su uso.
WO2014165291A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
EP4241784A3 (de) 2014-12-12 2023-11-15 CureVac SE Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression
AU2021385555B2 (en) * 2020-11-24 2024-05-23 MA, Muchou, Joe Dna vaccine for human palillomavirus and method for using the same
CN113637690A (zh) * 2021-08-18 2021-11-12 武汉华美生物工程有限公司 一种人乳头瘤病毒hpv16型e7活性蛋白的制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679509A (en) * 1993-09-28 1997-10-21 University Of New Mexico Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer
US5820868A (en) * 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
WO1996039178A1 (en) * 1995-06-05 1996-12-12 The Wistar Institute Of Anatomy And Biology A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
EP0969862B1 (de) * 1997-02-07 2006-10-18 Merck & Co., Inc. Synthetische hiv gag gene
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Also Published As

Publication number Publication date
ES2233437T3 (es) 2005-06-16
CA2381991A1 (en) 2001-03-01
DE60016765D1 (de) 2005-01-20
EP1212358B1 (de) 2004-12-15
JP2003511010A (ja) 2003-03-25
AU772611B2 (en) 2004-05-06
WO2001014416A2 (en) 2001-03-01
AU7063900A (en) 2001-03-19
EP1212358A2 (de) 2002-06-12
DE60016765T2 (de) 2005-11-24
WO2001014416A3 (en) 2001-12-06
JP4799789B2 (ja) 2011-10-26
PT1212358E (pt) 2005-04-29

Similar Documents

Publication Publication Date Title
ATE284898T1 (de) Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
ATE342916T1 (de) Synthetische hiv gag gene
HUP9901112A2 (hu) Szintetikus HIV-gének
TW200519203A (en) Optimized expression of HPV 58 L1 in yeast
WO1997048370A3 (en) Vaccines comprising synthetic genes
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
WO1999052503A3 (en) Rna cancer vaccine and methods for its use
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
ATE406453T1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
HUP0402259A2 (hu) Vakcinák
TW200602490A (en) Optimized expression of HPV 52 L1 in yeast
ATE285239T1 (de) Dna enthaltende impfstoffen
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2001046226A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2007134907A3 (en) Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
DE60310708D1 (de) In vivo stabilsierung von plasmiden
ZA200602107B (en) Piroplasmid vaccine
TW200801034A (en) Novel sea lice vaccine
EA199900726A1 (ru) Синтетические hiv gag гены
WO2004013281A3 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1212358

Country of ref document: EP

RZN Patent revoked